Page 62 - Read Online

Page 30 of 33 Berardi et al. J Cancer Metastasis Treat 2019;5:79 I http://dx.doi.org/10.20517/2394-4722.2019.008

41. Sata A, Hizuka N, Kawamata T, Hori T, Takano K. Hyponatremia after transsphenoidal surgery for hypothalamo-pituitary tumors.
Neuroendocrinology 2006;83:117-22.
42. Oren RM. Hyponatremia in congestive heart failure. Am J Cardiol 2005;95:2B-7B.
43. Gillum DM, Linas SL. Water intoxication in a psychotic patient with normal renal water excretion. Am J Med 1984;77:773-4.
44. Hillier TA, Abbott RD, Berrett EJ. Hyponatremia: evaluating the correction factor for hyperglycemia. Am J Med 1999;106:399-403.
45. Peri A, Grohé C, Berardi R, Runkle I. SIADH: differential diagnosis and clinical management. Endocrine 2017;55:311-9.
46. Cuesta M, Garrahy A, Thompson CJ. SIAD: practical recommendations for diagnosis and management. J Endocrinol Invest 2016;39:991-
100.
47. Petereit C, Zaba O, Teber I, Luders H, Grohe C. A rapid and efficient way to manage hyponatremia in patients with SIADH and small cell
lung cancer: treatment with tolvaptan. BMC Pulm Med 2013;13:55.
48. Berardi R, Armento G, Barni S, Caramanti M, Morgese F, et al. Disordini elettrolitici: raccomandazioni per l’iter diagnostic-terapuetico
nel paziente oncologico. AIOM 2018. Available from: https://www.aiom.it/wp-content/uploads/2018/11/2018_Raccomandazioni_
disordini_elettrolitici_AIOM.pdf [Last accessed on 26 Nov 2019]
49. Goh KP. Management of hyponatremia. Am Fam Phys 2004;69:2387-94.
50. Kraft MD, Btaiche IF, Sacks GS, Kudsk KA. Treatment of electrolyte disorders in adult patients in the intensive care unit. Am J Health
Syst Pharm 2005;62:1663-82.
51. Snyder NA, Feigal DW, Arieff AI. Hypernatremia in elderly patients. A heterogenous, morbid, and iatrogenic entity. Ann Intern Med
1987;107:309-19.
52. Kahn T. Hypernatremia in hospitalized patients: a sequel of inadvertent fluid administration - reply. Arch Intern Med 2000;160:1537-8.
53. Gipstein RM, Boyle JD. Hypernatremia complicating prolonged mannitol diuresis. N Engl J Med 1965;272:1116-7.
54. Loh JA, Verbalis JG. Diabetes insipidus as a complication after pituitary surgery. Nat Clin Pract Endocrinol Metab 2007;3:489-94.
55. Lindner G, Kneidinger N, Holzinger U, Druml W, Schwarz C. Tonicity balance in patients with hypernatremia acquired in the intensive
care unit. Am J Kidney Dis 2009;54:674-9.
56. Adroguè HJ, Madias EN. Hypernatremia. N Eng J Med 2000;342:1493-9.
57. Liamis G, Filippatos TD, Elisaf MS. Evaluation and treatment of hypernatremia: a practical guide for physicians. Postgrad Med
2016;128:299-306.
58. Rose BD. Clinical physiology of acid-base and electrolyte disorders. 5th ed. New York: Mcgraw-Hill; 2001.
59. Palevsky PM. Hypernatraemia. In Greenberg A, editor. Primer on Kidney Diseases. 2nd ed. San Diego: Academic Press; 1998. pp. 64-71.
60. Sands JM, Bichet DG, American College of P, American Physiological S. Nephrogenic diabetes insipidus. Ann Intern Med 2006;144:186-94.
61. Bailey RL, Dodd KW, Goldman JA, Gahche JJ, Dwyer JT, et al. Estimation of total usual calcium and vitamin D intakes in the United
States. J Nutr 2010;140:817-22.
62. Ashajyothi A, Pippalla RS, Satyavati D. Osteoporosis - an overview. IJPT 2010;2:847-61.
63. Carney SL. Calcitonin and human renal calcium and electrolyte transport. Miner Electrolyte Meta 1997;23:43-7.
64. DeLuca HF. Evolution of our understanding of vitamin D. Nutr Rev 2008;66:S73-87.
2+
65. Rizzuto R, Pozzan T. Microdomains of intracellular Ca : molecular determinants and functional consequences. Physiol Rev 2006;86:369-
408.
66. Grice DM, Vetter I, Faddy HM, Kenny PA, Roberts-Thomson SJ, et al. Golgi calcium pump secretory pathway calcium ATPase 1 (SPCA1)
is a key regulator of insulin-like growth factor receptor (IGF1R) processing in the basal-like breast cancer cell line MDA-MB-231. J Biol
Chem 2010;285:37458-66.
67. Vanden Abeele F, Zholos A, Bidaux G, Shuba Y, et al. Ca -independent phospholipase A2-dependent gating of TRPM8 by
2+
lysophospholipids. J Biol Chem 2006;281:40174-82.
68. Chodon D, Guilbert A, Dhennin-Duthille I, Gautier M, Telliez MS, et al. Estrogen regulation of TRPM8 expression in breast cancer cells.
BMC Cancer 2010;10:212.
2+
69. Fixemer T, Wissenbach U, Flockerzi V, Bonkhoff H. Expression of the Ca -selective cation channel TRPV6 in human prostate cancer: a
novel prognostic marker for tumor progression. Oncogene 2003;22:7858-61.
70. Tohme JF, Bilezikian JP. Hypocalcemic emergencies. Endocrinol Metab Clin North Am 1993;22:363-75.
71. Zhu W, Zhong M, Ai Z. Systematic evaluation of prophylactic neck dissection for the treatment of papillary thyroid carcinoma. Jpn J Clin
Oncol 2013;43:883-8.
72. Kukreja SC, Shanmugam A, Lad TE. Hypocalcemia in patients with prostate cancer. Calcif Tissue Int 1998;43:340-5.
73. McCormick BB, Davis J, Burns KD. Severe hypocalcemia following denosumab injection in a hemodialysis patient. Am J Kidney Dis
2012;60:626-8.
74. Hanamura M, Iwamoto T, Soga N, Sugimura Y, Okuda M. Risk factors contributing to the development of hypocalcemia after zoledronic
acid administration in patients with bone metastases of solid tumor. Biol Pharm Bull 2010;33:721-4.
75. Wang Q, Qi Y, Zhang D, Gong C, Yao A, et al. Electrolyte disorders assessment in solid tumor patients treated with anti-EGFR
monoclonal antibodies: a pooled analysis of 25 randomized clinical trials. Tumour Biol 2015;36:3471-82.
76. Tohme JF, Bilezikian JP. Hypocalcemic emergencies. Endocrinol Metab Clin North Am 1993;22:363-75.
77. Favus MJ, Bushinsky DA, Lemann JJ. Chapter 13. Regulation of calcium, magnesium, and phosphate metabolism. Am Soc Bone Miner
Res 2006. Available from: http://www.homepages.ucl.ac.uk/~ucgatma/Anat3048/PAPERS%20etc/ASBMR%20Primer%20Ed%206/
Ch%2013-18%20-%20Mineral%20Homeostasis.pdf [Last accessed on 26 Nov 2019]
78. Bushinsky DA, Monk RD. Electrolyte quintet: calcium. Lancet 1998;352:306-11.